JPMorgan analyst Andrew Polkowitz lowered the firm’s price target on Insperity (NSP) to $34 from $51 and keeps an Underweight rating on the shares. The company missed its guidance for the third consecutive quarter and lowered its 2025 adjusted EBITDA and earnings outlooks, primarily due to higher than anticipated health care cost trends, the analyst tells investors in a research note. The firm believes Insperity must restore investor confidence that it can manage benefits cost risk within its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSP: